Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, California, has announced that it will acquire Oobli, Inc., a Davis, California-based developer of fermentation-derived sweet proteins. Oobli’s ingredients are intended to help food and beverage brands reduce sugar while maintaining sweet taste.
The acquisition is intended to combine Amyris’s scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and represents a strategic commercial and technology expansion. The company expects the combination to accelerate its presence in protein- and peptide-based solutions across end markets.
Complementary platforms
Kathy Fortmann, Amyris’s chief executive officer, described Oobli as a commercial and technology platform that complements Amyris’s own. She said Oobli is positioned to change how sweetness reaches the market and that Amyris aims to contribute commercial scale and resources to accelerate that effort. According to Fortmann, combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden the company’s capabilities in food and beverage, personal care, flavors and fragrances, agriculture and other areas, expanding ways to help customers innovate.
Sweet-protein portfolio
Oobli’s commercial portfolio is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries near the equator. Oobli describes its sweet proteins as the first of their kind in the sugar-reduction category. According to Oobli, they are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, providing sweetness without gut disruption or blood sugar spikes.
The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. Oobli said the ingredients have FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. As consumers become more aware of metabolic health and sugar reduction, the company sees sweet proteins as a new tool for reducing sugar in categories including sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.
Scale and market reach
Ali Wing, Oobli’s chief executive officer, said the company has long believed there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. Wing said Oobli is proud of the breakthroughs it has achieved and that joining Amyris would provide the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann said Amyris has observed that biomanufactured solutions succeed when they align with consumer demand and market needs. She said Oobli’s platform meets that test by offering brands a way to address sweet taste, sugar reduction and clean label goals at the same time. Amyris said it looks forward to welcoming the Oobli team and realizing synergies between the two platforms.
Closing and continuity
The acquisition is expected to close in the coming weeks. Amyris said that as Oobli’s sweet-protein portfolio expands within the company, all existing customer commitments and brand partnerships will continue to be honored without interruption.
